LBA73 - Tivozanib–nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study

Background

The selective VEGFR TKI tivozanib has demonstrated single agent activity following VEGFR TKI and ICI, and in combination with ICI. TiNivo-2 was designed to test the combination of the PD-1 inhibitor nivolumab and tivozanib vs tivozanib monotherapy following tumor progression on prior ICI-based therapy.

Methods

TiNivo-2 enrolled pts with advanced clear-cell RCC who had 1–2 prior lines of therapy, including an ICI. Pts were randomized to receive tivozanib (0.89 mg) plus nivolumab or tivozanib alone (1.34 mg). The primary endpoint was PFS by independent radiology review (IRR); the key secondary endpoint was OS, other secondary endpoints included investigator-assessed PFS, ORR, DoR, and safety/tolerability. A sample size of 343 pts with 220 events provided ≥80% power to detect a 50% improvement in PFS, 12 m vs 8 m, assessed by IRR.

Results

343 pts were randomized to tivozanib–nivolumab (n=171) or tivozanib (n=172). Baseline characteristics were well balanced. With a median IRR-assessed PFS of 5.7 m for tivozanib–nivolumab and 7.4 m for tivozanib (HR 1.10 [95% CI 0.82. 1.43]), the study did not meet its primary endpoint. Among those with ICI as immediate prior therapy (n=244), mPFS was 7.4 m (95% CI, 5·55-9·56) with tivozanib–nivolumab and 9.2 m (95% CI, 7·43-9·99) with tivozanib. Data for subgroups and OS and ORR are in the table. 205 (60%) pts experienced a grade 3 or higher AE, the most common was hypertension (22% both arms; others <5%). AEs leading to death occurred in 7 (4.2%) pts with tivozanib–nivolumab and 5 (2.9%) with tivozanib; 1 (tivozanib arm) was deemed treatment related. Table: LBA73

Conclusions

ICI combination rechallenge did not improve clinical outcomes, suggesting the avoidance of sequential ICI in advanced RCC outside of clinical trials. These results support tivozanib monotherapy at 1.34 mg daily as 2nd-line therapy for pts following progression on previous ICI combination therapy.

Clinical trial identification

NCT04987203.

Editorial acknowledgement

Editorial assistance was provided by Michael Malia, PhD, of AVEO Oncology. The authors provided input and critical review at all stages and approved the final version for submission.

Legal entity responsible for the study

AVEO Pharmaceuticals, Inc.

Funding

AVEO Pharmaceuticals, Inc.

Disclosure

T.K. Choueiri: Financial Interests, Personal, Advisory Board, Advice on GU/RCC drugs: BMS, Pfizer, Merck, Exelixis, AstraZeneca; Financial Interests, Personal, Advisory Board, Advice on Onc drugs: Lilly, EMD Serono, Infinity; Financial Interests, Personal, Advisory Board, Advice on RCC drug: Calithera; Financial Interests, Personal, Invited Speaker, RCC drug: Ipsen; Financial Interests, Personal, Advisory Board, Advice on GU Onc drugs: Surface Oncology; Financial Interests, Personal, Other, Consultant on onc drugs: Analysis Group; Financial Interests, Personal, Invited Speaker, CME, ww2.peerview.com: Peerview; Financial Interests, Personal, Invited Speaker, CME, gotoper.com: PER; Financial Interests, Personal, Invited Speaker, CME, researchtopractice.com: ResearchToPractice; Financial Interests, Personal, Invited Speaker, National Association of Managed Care: NAMC; Financial Interests, Personal, Invited Speaker, ASCO-related event: ASCO-SITC; Financial Interests, Personal, Other, Grant review to Orien Network ($400): ORIEN; Financial Interests, Personal, Advisory Board, Advising oncology strategy: Aptitude Health; Financial Interests, Personal, Invited Speaker, Best of ASCO19 talk: Advent health; Financial Interests, Personal, Invited Speaker, Best of ESMO20 talk ($1000): UAE Society of Onc; Financial Interests, Personal, Invited Speaker, CME, mjhlifesciences.com (OncLive): MJH life sciences; Financial Interests, Personal, Invited Speaker, Grand Rounds: MDACC; Financial Interests, Personal, Invited Speaker, RCC webinar: Cancernet; Financial Interests, Personal, Invited Speaker, CME, Kidney Cancer Association ($1300): France Foundation; Financial Interests, Personal, Invited Speaker, CME, RCC: Springer, WebMed; Financial Interests, Personal, Invited Speaker, CME, ImmunoOncology in RCC: ASiM, CE; Financial Interests, Personal, Invited Speaker, CME, PodCast in RCC ($500.00): Caribou Publishing; Financial Interests, Personal, Invited Speaker, Reimbursement ($432.00): Kidney Cancer Association; Financial Interests, Personal, Other, member of the DSMB for clinical trial: Aravive; Financial Interests, Personal, Advisory Board, GU cancer drug development: alkermes, Gilead; Financial Interests, Personal, Other, Study section reviewer. $200.00 per day for 1 day: National Cancer Institute; Financial Interests, Personal, Other, Cancer Center Grand Rounds: Cleveland Clinic; Financial Interests, Personal, Advisory Board, Advisory Board/month: CURESPONSE; Financial Interests, Personal, Advisory Board: Tempest, Precede Bio (not publicly traded)); Financial Interests, Personal, Member of Board of Directors, unpaidhttps://www.accru.org/main/public/index.xhtml: ACCRU; Financial Interests, Personal, Member of Board of Directors, Unpaidhttps://kidneycan.org: KidneyCan; Financial Interests, Personal, Other, External Advisory Board Member: Gustave Roussy; Financial Interests, Personal, Stocks/Shares, advisor: Pionyr (not publicly traded), Tempest (publicly traded), Osel (not publicly traded), Precede Bio (not publicly traded)), CURESPONSE (not publicly traded), Inndura; Financial Interests, Personal, Stocks/Shares: Primium; Financial Interests, Personal, Royalties, For writing and updating chapters in GU Oncology: Up-To-Date online textbook; Financial Interests, Institutional, Funding, National Chair: BMS, Merck, Exelixis, AstraZeneca, Takeda, Tracon; Financial Interests, Institutional, Local PI, National Chair: Roche; Financial Interests, Institutional, Funding, National co-chair: Pfizer, EMD-Serono; Financial Interests, Institutional, Funding, Chair of trial: Lilly; Financial Interests, Institutional, Local PI: Surface Oncology, GSK; Financial Interests, Institutional, Funding, SC member: Eisai; Financial Interests, Institutional, Funding, National co-chair on 3 ongoing trials: ALLIANCE Cooperative Group; Financial Interests, Institutional, Research Grant, for GU oncology translational research through IION program: BMS; Financial Interests, Institutional, Research Grant, for GU oncology translational research: Exelixis; Financial Interests, Institutional, Research Grant, For Health outcomes research: Roche; Financial Interests, Institutional, Local PI, leads trials as PI: Nikang; Non-Financial Interests, Leadership Role, Co-Chair of the meeting, 2019- current and BOD member (unpaid): Kidney Cancer Research Summit of KidneyCAN; Non-Financial Interests, Principal Investigator, Trial Global and National PI with GU Cancers, mostly Kidney Cancer: Multiple Academic and Industry entities; Non-Financial Interests, Personal, Other, Track Leader/Session chair/Speaker/Discussant: ASCO; Non-Financial Interests, Personal, Other, Speaker/Discussant/Track Leader: ESMO; Non-Financial Interests, Institutional, Other, Access to genomic database: Foundation Med, Guardant, Invitae; Non-Financial Interests, Personal, Other, Grants reviewers: AACR; Non-Financial Interests, Personal, Other, Reviewer of papers: Various journals (e.g. NEJM, Lancet, JCO); Non-Financial Interests, Personal, Other, Medical writing and editorial assistance support (e.g. ClinicalThinking, Envision Pharma Group, Fishawack Group of Companies, Health Interactions, Parexel, Oxford PharmaGenesis, pharmagenesis, and others). However, first draft frequently initiated by myself when I am 1st author: Medical Communication; Non-Financial Interests, Member: ASCO, AACR; Non-Financial Interests, Other, Political vote usually as “independent”, not a member of any political party. I am an issue voter: General US Politics; Other, Employee at DFCI. Please see https://www.dana-farber.org/ for mission statement (non-profit hospital). I am also the past President of Medical Staff at DFCI 2015-2018: Dana-Farber Cancer Institute (DFCI); Other, Professor at HMS, Please see https://hms.harvard.edu/ for mission statement (non-profit school): Harvard Medical School (HMS); Other, The institution filed patents related to biomarkers of immune checkpoint blockers, and circulating tumor DNA. No money made and some patents were abandoned: Filed patents. R.J. Motzer: Financial Interests, Personal, Speaker, Consultant, Advisor: AVEO, Merck, Exelixis, Takeda; Financial Interests, Institutional, Research Funding: AVEO, Pfizer, Genentech/Roche, Easai, Merck, BMS, Exelixis; Financial Interests, Personal, Advisory Board: Incyte. K. Beckermann: Financial Interests, Institutional, Research Funding: BMS, LCFA, IASLC, Aravive, Pionyr, Arsenal Bio; Financial Interests, Personal, Speaker, Consultant, Advisor: Aravive, Aveo, Alpine Bioscience, Arcus, AstraZeneca, Adicet, BMS, Exelixis, Eisai, Merck, Nimbus, Xencor; Financial Interests, Personal, Speaker’s Bureau: Merck. P. Barthelemy: Financial Interests, Personal, Advisory Board: BMS, MSD, Merck, Pfizer, Ipsen, Bayer, Janssen Cilag, Astellas, Novartis, Amgen, Gilead; Financial Interests, Personal, Invited Speaker: AstraZeneca. R. Iacovelli: Financial Interests, Personal, Advisory Board: BMS, MSD, Janssen, Astellas, Ipsen, Pfizer, Bayer, Sanofi, Eisai, Merck; Financial Interests, Personal, Invited Speaker: Recordati; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Institutional, Local PI: MSD, Seagen, Aveo; Non-Financial Interests, Member: AIOM; Non-Financial Interests, Advisory Board, Italian Society of Uro-Oncology: SIUrO. S. Emambux: Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, AstraZeneca, Eisai, Janssen, BMS, Kephren; Financial Interests, Personal, Other, Travel expenses: Chugai; Financial Interests, Personal, Other, travel expenses: MSD, Pfizer, Janssen. J. Molina Cerrillo: Financial Interests, Personal, Speaker, Consultant, Advisor: Ipsen, Pfizer, Roche, Bayer, Sanofi, Janssen, Astellas, Eisai, Adacap, Eli Lilly, Novartis, BMS, MSD, Adium, Asofarma; Financial Interests, Personal, Other, travel: Ipsen, Pfizer, BMS, MSD; Financial Interests, Personal, Steering Committee Member, DSMB: Ipsen, Pfizer, Astellas, Eisai, BMS, MSD. B. Garmezy: Financial Interests, Institutional, Research Funding: AbbVie, Accutar Biotechnology, Arcus Biosciences, Arvinas, AstraZeneca, Aveo Oncology, Crispr Therapeutics, Eikon Therapeutics, Exelixis, Roche, Flare Therapeutics, Harbour Biomed, Ideaya Bioscience, Janssen, Janux, Jubilant Therapeutics, Kineta, Kinnate Biopharma, Loxo, Mink Therapeutics, Nuvation Bio, Profound Bio, Takeda, Teon Therapeutics, Tmunity Therapeutics, Xencore, Zenshine; Financial Interests, Institutional, Speaker, Consultant, Advisor: AbbVie, Adaptimmune, Adicent Therapeutics, AIQ Global, Amgen, Arcus Biosciences, Arvinas, AstraZeneca, Aveo, Bayer, Bicycle Tx, Eisai, EMD, Exelixis, Janssen, Merck, Novartis, Pfizer, Rondo Therapeutics, Sanofi, Seagen, Xencor. P.M. Coelho Barata: Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Eisai, Exelixis, Janssen, EMD Serono, Pfizer, Seattle Genetics, BMS, Bayer; Financial Interests, Personal, Invited Speaker: Caris Life Sciences, Telix; Financial Interests, Personal, Other, educational videos: UroToday; Financial Interests, Institutional, Steering Committee Member: Exelixis, Telix; Financial Interests, Institutional, Local PI: Merck. R.R. McKay: Financial Interests, Personal, Advisory Board: Aveo, AstraZeneca, Bayer, Calithera, Dendreon, Exelixis, JNJ, Merck, Pfizer, Sanofi, Tempus, BMS, Lilly, Sanofi, Seagen, Telix, Sorrento Therapeutics, Eisai, Blue Earth Diagnostics; Financial Interests, Personal, Other, Molecular tumor board: Caris; Financial Interests, Personal, Other, Consultant: Dendreon, Myovant; Financial Interests, Personal, Invited Speaker: Exelixis, Merck, Novartis, Pfizer; Financial Interests, Steering Committee Member: Aveo, Merck, Eli Lilly; Financial Interests, Local PI: JNJ, Seagen, Calibr, Poseida, Oncternal, Scholar Rock, Merck, Xencor, Genentech, Eli Lilly, BMS; Financial Interests, Trial Chair: Bayer, AstraZeneca; Financial Interests, Institutional, Local PI: Exelixis. A. Chehrazi-Raffle: Financial Interests, Personal, Advisory Board: Exelixis, Inc, Aveo Inc., Pfizer Inc.; Financial Interests, Personal, Invited Speaker: Exelixis, Inc, OncLive/MJH Life Sciences, ASCO Direct. H. Hammers: Financial Interests, Institutional, Other, clinical trial support: merck, BMS, Eisai, Agenus, Hoosier, Aveo; Financial Interests, Personal, Speaker, Consultant, Advisor: Eisai, Aveo, Pfizer, BMS. D.Y.C. Heng: Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer, Novartis, BMS, Janssen, Astellas, Ipsen, Eisai, Merck; Financial Interests, Institutional, Research Funding: Pfizer, Novartis, Exelixis, BMS, Ipsen. E. Braendle: Financial Interests, Personal, Full or part-time Employment: Aveo Oncology. B.A. McGregor: Financial Interests, Personal, Advisory Board: Exelixis, BMS, Dendreon, Seagen, Astellas, Eisai, Pfizer, Gilead, Arcus, Loxo/Lilly; Financial Interests, Personal, Invited Speaker: EMD Serono, Seagen; Financial Interests, Institutional, Trial Chair: Pfizer, Exelixis, Exelixis, BMS, Gilead; Financial Interests, Institutional, Local PI: Calithera, Seagen, Aveo; Non-Financial Interests, Member: ASCO. L. Albiges: Financial Interests, Institutional, Other, Consulting: Astellas, BMS, EISAI, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche, Merck, Amgen; Financial Interests, Institutional, Other, Honoraria: Novartis; Non-Financial Interests, Principal Investigator, Clinical trial steering committee: Pfizer, BMS, Aveo, AstraZeneca, MSD; Non-Financial Interests, Principal Investigator: Ipsen; Non-Financial Interests, Other, Clinical trial steering committee: Roche, Exelixis; Non-Financial Interests, Member: ASCO; Non-Financial Interests, Other, Medical Steering Committee: Kidney Cancer Association; Non-Financial Interests, Other, Member of the Renal Cell Carcinoma Guidelines Panel: European Association of Urology (EAU).